Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

Authors

null

Jonathan R. Strosberg

Moffitt Cancer Center, Tampa, FL

Jonathan R. Strosberg , Martyn E Caplin , Pamela L. Kunz , Philippe B Ruszniewski , Lisa Bodei , Andrew Eugene Hendifar , Erik Mittra , Edward M. Wolin , James C. Yao , Marianne E Pavel , Enrique Grande , Eric Van Cutsem , Ettore Seregni , Hugo Duarte , Germo Gericke , Amy Bartalotta , Arnaud Demange , Sakir Mutevelic , Eric Krenning

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT01578239

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4112)

DOI

10.1200/JCO.2021.39.15_suppl.4112

Abstract #

4112

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

Safety of <sup>177</sup>Lu‑DOTATATE in patients with advanced neuroendocrine tumors: Data from a U.S. expanded access program.

Safety of 177Lu‑DOTATATE in patients with advanced neuroendocrine tumors: Data from a U.S. expanded access program.

First Author: Martin S. Auerbach

Poster

2017 Gastrointestinal Cancers Symposium

Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.

Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.

First Author: Jonathan R. Strosberg

First Author: Thierry Andre